Congenital Disorders of the Hypothalamo-Pituitary-Somatotrope Axis

Brook's Clinical Pediatric Endocrinology: Sixth Edition

Volumn , Issue , 2010, Pages 60-105

  Mehta, Ameeta ^a   Gevers, Evelien F ^a   Dattani, Mehul T ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Anterior pituitary somatotropes, thyrotropes, corticotropes, gonadotropes and lactotropes; Arginine vasopressin basic nanopeptide with disulfide bridge between cysteine residues; Combined pituitary hormone deficiency (CPHD); Congenital disorders of hypothalamo pituitary somatotrope axis; Noonan syndrome abnormalities within signaling pathways and GH signaling; Pro opiomelanocortin (POMC) precursor to melanocyte stimulating hormone (MSH) and endorphins; Septo optic dysplasia (SOD) rare congenital heterogeneous anomaly; Terminal pituitary cell differentiation; Thyroid stimulating hormone two non covalently bound chains of amino acids; Thyrotropin releasing hormone (TRH) stimulating release of TSH and prolactin

Indexed keywords

EID: 80052464238     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444316728.ch4     Document Type: Chapter

References (347)

1. Cohen LE, Radovick S. Molecular basis of combined pituitary hormone deficiencies. Endocr Rev 2002; 23: 431-442.
2. Dattani MT, Robinson IC. The molecular basis for developmental disorders of the pituitary gland in man. Clin Genet 2000; 57: 337-346.
3. Dasen JS, Rosenfeld MG. Signaling and transcriptional mechanisms in pituitary development. Annu Rev Neurosci 2001; 24: 327-355.
4. Rizzoti K, Lovell-Badge R. Early development of the pituitary gland: induction and shaping of Rathke's pouch. Rev Endocr Metab Disord 2005; 6: 161-172.
5. Zhu X, Zhang J, Tollkuhn J, Ohsawa R, Bresnick EH, Guillemot F, et al. Sustained Notch signaling in progenitors is required for sequential emergence of distinct cell lineages during organogenesis. Genes Dev 2006; 20: 2739-2753.
6. Thomas PQ, Johnson BV, Rathjen J, Rathjen PD. Sequence, genomic organization, and expression of the novel homeobox gene Hesx1. J Biol Chem 1995; 270: 3869-3875.
7. Hermesz E, Mackem S, Mahon KA. Rpx: a novel anterior-restricted homeobox gene progressively activated in the prechordal plate, anterior neural plate and Rathke's pouch of the mouse embryo. Development 1996; 122: 41-52.
8. Dattani MT, Martinez-Barbera JP, Thomas PQ, Brickman JM, Gupta R, Martensson IL, et al. Mutations in the homeobox gene HESX1/Hesx1 associated with septo-optic dysplasia in human and mouse. Nat Genet 1998; 19: 125-133.
9. Thomas PQ, Dattani MT, Brickman JM, McNay D, Warne G, Zacharin M, et al. Heterozygous HESX1 mutations associated with isolated congenital pituitary hypoplasia and septo-optic dysplasia. Hum Mol Genet 2001; 10: 39-45.
10. Carvalho LR, Woods KS, Mendonca BB, Marcal N, Zamparini AL, Stifani S, et al. A homozygous mutation in HESX1 is associated with evolving hypopituitarism due to impaired repressor-corepressor interaction. J Clin Invest 2003; 112: 1192-1201.
11. Brickman JM, Clements M, Tyrell R, McNay D, Woods K, Warner J, et al. Molecular effects of novel mutations in Hesx1/HESX1 associated with human pituitary disorders. Development 2001; 128: 5189-5199.
12. Cohen RN, Cohen LE, Botero D, Yu C, Sagar A, Jurkiewicz M, et al. Enhanced repression by HESX1 as a cause of hypopituitarism and septooptic dysplasia. J Clin Endocrinol Metab 2003; 88: 4832-4839.
13. Tajima T, Hattorri T, Nakajima T, Okuhara K, Sato K, Abe S, et al. Sporadic heterozygous frameshift mutation of HESX1 causing pituitary and optic nerve hypoplasia and combined pituitary hormone deficiency in a Japanese patient. J Clin Endocrinol Metab 2003; 88: 45-50.
14. Semina EV, Reiter R, Leysens NJ, Alward WL, Small KW, Datson NA, et al. Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndrome. Nat Genet 1996; 14: 392-399.
15. Schmitt S, Biason-Lauber A, Betts D, Schoenle EJ. Genomic structure, chromosomal localization, and expression pattern of the human LIM-homeobox3 (LHX 3) gene. Biochem Biophys Res Commun 2000; 274: 49-56.
16. Zhadanov AB, Bertuzzi S, Taira M, Dawid IB, Westphal H. Expression pattern of the murine LIM class homeobox gene Lhx3 in subsets of neural and neuroendocrine tissues. Dev Dyn 1995; 202: 354-364.
17. Bach I, Rhodes SJ, Pearse RV, Heinzel T, Gloss B, Scully KM, et al. P-Lim, a LIM homeodomain factor, is expressed during pituitary organ and cell commitment and synergizes with Pit-1. Proc Natl Acad Sci U S A 1995; 92: 2720-2724.
18. Ellsworth BS, Butts DL, Camper SA. Mechanisms underlying pituitary hypoplasia and failed cell specification in Lhx3-deficient mice. Dev Biol 2008; 313: 118-129.
19. Sheng HZ, Moriyama K, Yamashita T, Li H, Potter SS, Mahon KA, et al. Multistep control of pituitary organogenesis. Science 1997; 278: 1809-1812.
20. Sobrier ML, Attie-Bitach T, Netchine I, Encha-Razavi F, Vekemans M, Amselem S. Pathophysiology of syndromic combined pituitary hormone deficiency due to a LHX3 defect in light of LHX3 and LHX4 expression during early human development. Gene Expr Patterns 2004; 5: 279-284.
21. Netchine I, Sobrier ML, Krude H, Schnabel D, Maghnie M, Marcos E, et al. Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nat Genet 2000; 25: 182-186.
22. Pfaeffle RW, Savage JJ, Hunter CS, Palme C, Ahlmann M, Kumar P, et al. Four novel mutations of the LHX3 gene cause combined pituitary hormone deficiencies with or without limited neck rotation. J Clin Endocrinol Metab 2007; 92: 1909-1919.
23. Pfaeffle RW, Hunter CS, Savage JJ, Duran-Prado M, Mullen RD, Neeb ZP, et al. Three novel missense mutations within the LHX4 gene are associated with variable pituitary hormone deficiencies. J Clin Endocrinol Metab 2008; 93: 1062-1071.
24. Machinis K, Pantel J, Netchine I, Leger J, Camand OJ, Sobrier ML, et al. Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4. Am J Hum Genet 2001; 69: 961-968.
25. Tajima T, Hattori T, Nakajima T, Okuhara K, Tsubaki J, Fujieda K. A novel missense mutation (P366T) of the LHX4 gene causes severe combined pituitary hormone deficiency with pituitary hypoplasia, ectopic posterior lobe and a poorly developed sella turcica. Endocr J 2007; 54: 637-641.
26. Gubbay J, Collignon J, Koopman P, Capel B, Economou A, Munsterberg A, et al. A gene mapping to the sex-determining region of the mouse Y chromosome is a member of a novel family of embryonically expressed genes. Nature 1990; 346: 245-250.
27. Stevanovic M, Lovell-Badge R, Collignon J, Goodfellow PN. SOX3 is an X-linked gene related to SRY. Hum Mol Genet 1993; 2: 2013-2018.
28. Pevny LH, Lovell-Badge R. Sox genes find their feet. Curr Opin Genet Dev 1997; 7: 338-344.
29. Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 1999; 27: 1409-1420.
30. Bowles J, Schepers G, Koopman P. Phylogeny of the SOX family of developmental transcription factors based on sequence and structural indicators. Dev Biol 2000; 227: 239-255.
31. Stevanovic M, Zuffardi O, Collignon J, Lovell-Badge R, Goodfellow P. The cDNA sequence and chromosomal location of the human SOX2 gene. Mamm Genome 1994; 5: 640-642.
32. Pevny L, Placzek M. SOX genes and neural progenitor identity. Curr Opin Neurobiol 2005; 15: 7-13.
33. Bylund M, Andersson E, Novitch BG, Muhr J. Vertebrate neurogenesis is counteracted by Sox1-3 activity. Nat Neurosci 2003; 6: 1162-1168.
34. Rizzoti K, Brunelli S, Carmignac D, Thomas PQ, Robinson IC, Lovell-Badge R. SOX3 is required during the formation of the hypothalamo-pituitary axis. Nat Genet 2004; 36: 247-255.
35. Weiss J, Meeks JJ, Hurley L, Raverot G, Frassetto A, Jameson JL. Sox3 is required for gonadal function, but not sex determination, in males and females. Mol Cell Biol 2003; 23: 8084-8091.
36. Hamel BC, Smits AP, Otten BJ, van den HB, Ropers HH, Mariman EC. Familial X-linked mental retardation and isolated growth hormone deficiency: clinical and molecular findings. Am J Med Genet 1996; 64: 35-41.
37. Hol FA, Schepens MT, van Beersum SE, Redolfi E, Affer M, Vezzoni P, et al. Identification and characterization of an Xq26-q27 duplication in a family with spina bifida and panhypopituitarism suggests the involvement of two distinct genes. Genomics 2000; 69: 174-181.
38. Woods KS, Cundall M, Turton J, Rizotti K, Mehta A, Palmer R, et al. Over-and underdosage of SOX3 is associated with infundibular hypoplasia and hypopituitarism. Am J Hum Genet 2005; 76: 833-849.
39. Solomon NM, Nouri S, Warne GL, Lagerstrom-Fermer M, Forrest SM, Thomas PQ. Increased gene dosage at Xq26-q27 is associated with X-linked hypopituitarism. Genomics 2002; 79: 553-559.
40. Laumonnier F, Ronce N, Hamel BC, Thomas P, Lespinasse J, Raynaud M, et al. Transcription factor SOX3 is involved in X-linked mental retardation with growth hormone deficiency. Am J Hum Genet 2002; 71: 1450-1455.
41. Wood HB, Episkopou V. Comparative expression of the mouse Sox1, Sox2 and Sox3 genes from pre-gastrulation to early somite stages. Mech Dev 1999; 86: 197-201.
42. Williamson KA, Hever AM, Rainger J, Rogers RC, Magee A, Fiedler Z, et al. Mutations in SOX2 cause anophthalmia-esophageal-genital (AEG) syndrome. Hum Mol Genet 2006; 15: 1413-1422.
43. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003; 17: 126-140.
44. Taranova OV, Magness ST, Fagan BM, Wu Y, Surzenko N, Hutton SR, et al. SOX2 is a dose-dependent regulator of retinal neural progenitor competence. Genes Dev 2006; 20: 1187-1202.
45. Kelberman D, Rizzoti K, Avilion A, Bitner-Glindzicz M, Cianfarani S, Collins J, et al. Mutations within Sox2/SOX2 are associated with abnormalities in the hypothalamo-pituitary-gonadal axis in mice and humans. J Clin Invest 2006; 116: 2442-2455.
46. Sornson MW, Wu W, Dasen JS, Flynn SE, Norman DJ, O'Connell SM, et al. Pituitary lineage determination by the Prophet of Pit-1 homeodomain factor defective in Ames dwarfism. Nature 1996; 384: 327-333.
47. Parks JS, Brown MR, Hurley DL, Phelps CJ, Wajnrajch MP. Heritable disorders of pituitary development. J Clin Endocrinol Metab 1999; 84: 4362-4370.
48. Olson LE, Tollkuhn J, Scafoglio C, Krones A, Zhang J, Ohgi KA, et al. Homeodomain-mediated beta-catenin-dependent switching events dictate cell-lineage determination. Cell 2006; 125: 593-605.
49. Ward RD, Raetzman LT, Suh H, Stone BM, Nasonkin IO, Camper SA. Role of PROP1 in pituitary gland growth. Mol Endocrinol 2005; 19: 698-710.
50. Ward RD, Stone BM, Raetzman LT, Camper SA. Cell proliferation and vascularization in mouse models of pituitary hormone deficiency. Mol Endocrinol 2006; 20: 1378-1390.
51. Wu W, Cogan JD, Pfaffle RW, Dasen JS, Frisch H, O'Connell SM, et al. Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet 1998; 18: 147-149.
52. Li S, Crenshaw EB, III, Rawson EJ, Simmons DM, Swanson LW, Rosenfeld MG. Dwarf locus mutants lacking three pituitary cell types result from mutations in the POU-domain gene pit-1. Nature 1990; 347: 528-533.
53. Andersen B, Rosenfeld MG. POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. Endocr Rev 2001; 22: 2-35.
54. Tatsumi K, Miyai K, Notomi T, Kaibe K, Amino N, Mizuno Y, et al. Cretinism with combined hormone deficiency caused by a mutation in the PIT1 gene. Nat Genet 1992; 1: 56-58.
55. Bennani-Baiti IM, Asa SL, Song D, Iratni R, Liebhaber SA, Cooke NE. DNase I-hypersensitive sites I and II of the human growth hormone locus control region are a major developmental activator of somatotrope gene expression. Proc Natl Acad Sci U S A 1998; 95: 10655-10660.
56. Baumann G. Genetic characterization of growth hormone deficiency and resistance: implications for treatment with recombinant growth hormone. Am J Pharmacogenomics 2002; 2: 93-111.
57. Carter-Su C, King AP, Argetsinger LS, Smit LS, Vanderkuur J, Campbell GS. Signalling pathway of GH. Endocr J 1996; 43 (Suppl): S65-S70.
58. Smit LS, Meyer DJ, Billestrup N, Norstedt G, Schwartz J, Carter-Su C. The role of the growth hormone (GH) receptor and JAK1 and JAK2 kinases in the activation of Stats 1, 3, and 5 by GH. Mol Endocrinol 1996; 10: 519-533.
59. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-660.
60. Illig R. Growth hormone antibodies in patients treated with different preparations of human growth hormone (HGH). J Clin Endocrinol Metab 1970; 31: 679-688.
61. Phillips JA III, Hjelle BL, Seeburg PH, Zachmann M. Molecular basis for familial isolated growth hormone deficiency. Proc Natl Acad Sci U S A 1981; 78: 6372-6375.
62. Wajnrajch MP, Gertner JM, Harbison MD, Chua SC Jr, Leibel RL. Nonsense mutation in the human growth hormone-releasing hormone receptor causes growth failure analogous to the little (lit) mouse. Nat Genet 1996; 12: 88-90.
63. Carakushansky M, Whatmore AJ, Clayton PE, Shalet SM, Gleeson HK, Price DA, et al. A new missense mutation in the growth hormone-releasing hormone receptor gene in familial isolated GH deficiency. Eur J Endocrinol 2003; 148: 25-30.
64. Hess O, Hujeirat Y, Wajnrajch MP, Allon-Shalev S, Zadik Z, Lavi I, et al. Variable phenotypes in familial isolated growth hormone deficiency caused by a G6664A mutation in the GH-1 gene. J Clin Endocrinol Metab 2007; 92: 4387-4393.
65. Moseley CT, Mullis PE, Prince MA, Phillips JA III. An exon splice enhancer mutation causes autosomal dominant GH deficiency. J Clin Endocrinol Metab 2002; 87: 847-852.
66. McGuinness L, Magoulas C, Sesay AK, Mathers K, Carmignac D, Manneville JB, et al. Autosomal dominant growth hormone deficiency disrupts secretory vesicles in vitro and in vivo in transgenic mice. Endocrinology 2003; 144: 720-731.
67. Salemi S, Yousefi S, Baltensperger K, Robinson IC, Eble A, Simon D, et al. Variability of isolated autosomal dominant GH deficiency (IGHD II): impact of the P89L GH mutation on clinical follow-up and GH secretion. Eur J Endocrinol 2005; 153: 791-802.
68. Turton JP, Buchanan CR, Robinson IC, Aylwin SJ, Dattani MT. Evolution of gonadotropin deficiency in a patient with type II autosomal dominant GH deficiency. Eur J Endocrinol 2006; 155: 793-799.
69. Collu R, Tang J, Castagne J, Lagace G, Masson N, Huot C, et al. A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J Clin Endocrinol Metab 1997; 82: 1561-1565.
70. Dacou-Voutetakis C, Feltquate DM, Drakopoulou M, Kourides IA, Dracopoli NC. Familial hypothyroidism caused by a nonsense mutation in the thyroid-stimulating hormone beta-subunit gene. Am J Hum Genet 1990; 46: 988-993.
71. Lin L, Hindmarsh PC, Metherell LA, Alzyoud M, Al Ali M, Brain CE, et al. Severe loss-of-function mutations in the adrenocorticotropin receptor (ACTHR, MC2R) can be found in patients diagnosed with salt-losing adrenal hypoplasia. Clin Endocrinol (Oxf ) 2007; 66: 205-210.
72. Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998; 19: 155-157.
73. Jackson RS, Creemers JW, Ohagi S, Raffin-Sanson ML, Sanders L, Montague CT, et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997; 16: 303-306.
74. O'Rahilly S, Gray H, Humphreys PJ, Krook A, Polonsky KS, White A, et al. Brief report: impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med 1995; 333: 1386-1390.
75. Jackson RS, Creemers JW, Farooqi IS, Raffin-Sanson ML, Varro A, Dockray GJ, et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest 2003; 112: 1550-1560.
76. Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A, et al. A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 2001; 104: 849-859.
77. Fromantin M, Gineste J, Didier A, Rouvier J. [Impuberism and hypogonadism at induction into military service. Statistical study]. Probl Actuels Endocrinol Nutr 1973; 16: 179-199.
78. Filippi G. Klinefelter's syndrome in Sardinia. Clinical report of 265 hypogonadic males detected at the time of military check-up. Clin Genet 1986; 30: 276-284.
79. Quinton R, Duke VM, de Zoysa PA, Platts AD, Valentine A, Kendall B, et al. The neuroradiology of Kallmann's syndrome: a genotypic and phenotypic analysis. J Clin Endocrinol Metab 1996; 81: 3010-3017.
80. Bick D, Franco B, Sherins RJ, Heye B, Pike L, Crawford J, et al. Brief report: intragenic deletion of the KALIG-1 gene in Kallmann's syndrome. N Engl J Med 1992; 326: 1752-1755.
81. Hardelin JP, Levilliers J, Blanchard S, Carel JC, Leutenegger M, Pinard-Bertelletto JP, et al. Heterogeneity in the mutations responsible for X chromosome-linked Kallmann syndrome. Hum Mol Genet 1993; 2: 373-377.
82. Tabarin A, Achermann JC, Recan D, Bex V, Bertagna X, Christin-Maitre S, et al. A novel mutation in DAX1 causes delayed-onset adrenal insufficiency and incomplete hypogonadotropic hypogonadism. J Clin Invest 2000; 105: 321-328.
83. de Roux N, Young J, Misrahi M, Genet R, Chanson P, Schaison G, et al. A family with hypogonadotropic hypogonadism and mutations in the gonadotropin-releasing hormone receptor. N Engl J Med 1997; 337: 1597-1602.
84. Lin L, Ercan O, Raza J, Burren CP, Creighton SM, Auchus RJ, et al. Variable phenotypes associated with aromatase (CYP19) insufficiency in humans. J Clin Endocrinol Metab 2007; 92: 982-990.
85. de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proc Natl Acad Sci U S A 2003; 100: 10972-10976.
86. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997; 387: 903-908.
87. Farooqi IS, Wangensteen T, Collins S, Kimber W, Matarese G, Keogh JM, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 2007; 356: 237-247.
88. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879-884.
89. Kauppila A, Chatelain P, Kirkinen P, Kivinen S, Ruokonen A. Isolated prolactin deficiency in a woman with puerperal alactogenesis. J Clin Endocrinol Metab 1987; 64: 309-312.
90. Ito M, Oiso Y, Murase T, Kondo K, Saito H, Chinzei T, et al. Possible involvement of inefficient cleavage of preprovasopressin by signal peptidase as a cause for familial central diabetes insipidus. J Clin Invest 1993; 91: 2565-2571.
91. Bahnsen U, Oosting P, Swaab DF, Nahke P, Richter D, Schmale H. A missense mutation in the vasopressin-neurophysin precursor gene cosegregates with human autosomal dominant neurohypophyseal diabetes insipidus. EMBO J 1992; 11: 19-23.
92. Nagasaki H, Ito M, Yuasa H, Saito H, Fukase M, Hamada K, et al. Two novel mutations in the coding region for neurophysin-II associated with familial central diabetes insipidus. J Clin Endocrinol Metab 1995; 80: 1352-1356.
93. Cryns K, Sivakumaran TA, van den Ouweland JM, Pennings RJ, Cremers CW, Flothmann K, et al. Mutational spectrum of the WFS1 gene in Wolfram syndrome, nonsyndromic hearing impairment, diabetes mellitus, and psychiatric disease. Hum Mutat 2003; 22: 275-287.
94. Mehta A, Hindmarsh PC, Stanhope RG, Turton JP, Cole TJ, Preece MA, et al. The role of growth hormone in determining birth size and early postnatal growth, using congenital growth hormone deficiency (GHD) as a model. Clin Endocrinol (Oxf) 2005; 63: 223-231.
95. Pena-Almazan S, Buchlis J, Miller S, Shine B, MacGillivray M. Linear growth characteristics of congenitally GH-deficient infants from birth to one year of age. J Clin Endocrinol Metab 2001; 86: 5691-5694.
96. Craft WH, Underwoood LE, Van Wyk JJ. High incidence of perinatal insult in children with idiopathic hypopituitarism. J Pediatr 1980; 96(3 Pt 1): 397-402.
97. Deladoey J, Fluck C, Buyukgebiz A, Kuhlmann BV, Eble A, Hindmarsh PC, et al. "Hot spot" in the PROP1 gene responsible for combined pituitary hormone deficiency. J Clin Endocrinol Metab 1999; 84: 1645-1650.
98. Cogan JD, Wu W, Phillips JA, III, Arnhold IJ, Agapito A, Fofanova OV, et al. The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. J Clin Endocrinol Metab 1998; 83: 3346-3349.
99. Turton JP, Mehta A, Raza J, Woods KS, Tiulpakov A, Cassar J, et al. Mutations within the transcription factor PROP1 are rare in a cohort of patients with sporadic combined pituitary hormone deficiency (CPHD). Clin Endocrinol (Oxf ) 2005; 63: 10-18.
100. Mendonca BB, Osorio MG, Latronico AC, Estefan V, Lo LS, Arnhold IJ. Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene. J Clin Endocrinol Metab 1999; 84: 942-945.
101. Arroyo A, Pernasetti F, Vasilyev VV, Amato P, Yen SS, Mellon PL. A unique case of combined pituitary hormone deficiency caused by a PROP1 gene mutation (R120C) associated with normal height and absent puberty. Clin Endocrinol (Oxf ) 2002; 57: 283-291.
102. Asteria C, Oliveira JH, Abucham J, Beck-Peccoz P. Central hypocortisolism as part of combined pituitary hormone deficiency due to mutations of PROP-1 gene. Eur J Endocrinol 2000; 143: 347-352.
103. Pernasetti F, Toledo SP, Vasilyev VV, Hayashida CY, Cogan JD, Ferrari C, et al. Impaired adrenocorticotropin-adrenal axis in com bined pituitary hormone deficiency caused by a two-base pair deletion (301-302delAG) in the prophet of Pit-1 gene. J Clin Endocrinol Metab 2000; 85: 390-397.
104. Riepe FG, Partsch CJ, Blankenstein O, Monig H, Pfaffle RW, Sippell WG. Longitudinal imaging reveals pituitary enlargement preceding hypoplasia in two brothers with combined pituitary hormone deficiency attributable to PROP1 mutation. J Clin Endocrinol Metab 2001; 86: 4353-4357.
105. Agarwal G, Bhatia V, Cook S, Thomas PQ. Adrenocorticotropin deficiency in combined pituitary hormone deficiency patients homozygous for a novel PROP1 deletion. J Clin Endocrinol Metab 2000; 85: 4556-4561.
106. Vallette-Kasic S, Barlier A, Teinturier C, Diaz A, Manavela M, Berthezene F, et al. PROP1 gene screening in patients with multiple pituitary hormone deficiency reveals two sites of hypermutability and a high incidence of corticotroph deficiency. J Clin Endocrinol Metab 2001; 86: 4529-4535.
107. Voutetakis A, Argyropoulou M, Sertedaki A, Livadas S, Xekouki P, Maniati-Christidi M, et al. Pituitary magnetic resonance imaging in 15 patients with Prop1 gene mutations: pituitary enlargement may originate from the intermediate lobe. J Clin Endocrinol Metab 2004; 89: 2200-2206.
108. Cohen LE, Zanger K, Brue T, Wondisford FE, Radovick S. Defective retinoic acid regulation of the Pit-1 gene enhancer: a novel mechanism of combined pituitary hormone deficiency. Mol Endocrinol 1999; 13: 476-484.
109. Pfaffle RW, DiMattia GE, Parks JS, Brown MR, Wit JM, Jansen M, et al. Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science 1992; 257: 1118-1121.
110. Pfaffle RW, Martinez R, Kim C, Frisch H, Lebl J, Otten B, et al. GH and TSH deficiency. Exp Clin Endocrinol Diabetes 1997; 105 (Suppl 4): 1-5.
111. Turton JP, Reynaud R, Mehta A, Torpiano J, Saveanu A, Woods KS, et al. Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency (CPHD). J Clin Endocrinol Metab 2005; 90: 4762-4770.
112. Cohen LE, Wondisford FE, Salvatoni A, Maghnie M, Brucker-Davis F, Weintraub BD, et al. A "hot spot" in the Pit-1 gene responsible for combined pituitary hormone deficiency: clinical and molecular correlates. J Clin Endocrinol Metab 1995; 80: 679-684.
113. Ohta K, Nobukuni Y, Mitsubuchi H, Fujimoto S, Matsuo N, Inagaki H, et al. Mutations in the Pit-1 gene in children with combined pituitary hormone deficiency. Biochem Biophys Res Commun 1992; 189: 851-855.
114. Radovick S, Nations M, Du Y, Berg LA, Weintraub BD, Wondisford FE. A mutation in the POU-homeodomain of Pit-1 responsible for combined pituitary hormone deficiency. Science 1992; 257: 1115-1118.
115. Okamoto N, Wada Y, Ida S, Koga R, Ozono K, Chiyo H, et al. Monoallelic expression of normal mRNA in the PIT1 mutation heterozygotes with normal phenotype and biallelic expression in the abnormal phenotype. Hum Mol Genet 1994; 3: 1565-1568.
116. Holl RW, Pfaffle R, Kim C, Sorgo W, Teller WM, Heimann G. Combined pituitary deficiencies of growth hormone, thyroid stimulating hormone and prolactin due to Pit-1 gene mutation: a case report. Eur J Pediatr 1997; 156: 835-837.
117. Aarskog D, Eiken HG, Bjerknes R, Myking OL. Pituitary dwarfism in the R271W Pit-1 gene mutation. Eur J Pediatr 1997; 156: 829-834.
118. Rodrigues Martineli AM, Braga M, De Lacerda L, Raskin S, Graf H. Description of a Brazilian patient bearing the R271W Pit-1 gene mutation. Thyroid 1998; 8: 299-304.
119. Ward L, Chavez M, Huot C, Lecocq P, Collu R, Decarie JC, et al. Severe congenital hypopituitarism with low prolactin concentrations and age-dependent anterior pituitary hypoplasia: a clue to a PIT-1 mutation. J Pediatr 1998; 132: 1036-1038.
120. Tornqvist K, Ericsson A, Kallen B. Optic nerve hypoplasia: risk factors and epidemiology. Acta Ophthalmol Scand 2002; 80: 300-304.
121. Patel L, McNally RJ, Harrison E, Lloyd IC, Clayton PE. Geographical distribution of optic nerve hypoplasia and septo-optic dysplasia in Northwest England. J Pediatr 2006; 148: 85-88.
122. Arslanian SA, Rothfus WE, Foley TP Jr, Becker DJ. Hormonal, metabolic, and neuroradiologic abnormalities associated with septo-optic dysplasia. Acta Endocrinol (Copenh) 1984; 107: 282-288.
123. Morishima A, Aranoff GS. Syndrome of septo-optic-pituitary dysplasia: the clinical spectrum. Brain Dev 1986; 8: 233-239.
124. Brodsky MC, Glasier CM. Optic nerve hypoplasia. Clinical significance of associated central nervous system abnormalities on magnetic resonance imaging. Arch Ophthalmol 1993; 111: 66-74.
125. Zeki SM, Hollman AS, Dutton GN. Neuroradiological features of patients with optic nerve hypoplasia. J Pediatr Ophthalmol Strabismus 1992; 29: 107-112.
126. Birkebaek NH, Patel L, Wright NB, Grigg JR, Sinha S, Hall CM, et al. Endocrine status in patients with optic nerve hypoplasia: relationship to midline central nervous system abnormalities and appearance of the hypothalamic-pituitary axis on magnetic resonance imaging. J Clin Endocrinol Metab 2003; 88: 5281-5286.
127. Nanduri VR, Stanhope R. Why is the retention of gonadotrophin secretion common in children with panhypopituitarism due to septo-optic dysplasia? Eur J Endocrinol 1999; 140: 48-50.
128. Pagon RA, Stephan MJ. Septo-optic dysplasia with digital anomalies. J Pediatr 1984; 105: 966-968.
129. Orrico A, Galli L, Zappella M, Monti L, Vatti GP, Venturi C, et al. Septo-optic dysplasia with digital anomalies associated with maternal multidrug abuse during pregnancy. Eur J Neurol 2002; 9: 679-682.
130. Harrison IM, Brosnahan D, Phelan E, Fitzgerald RJ, Reardon W. Septo-optic dysplasia with digital anomalies: a recurrent pattern syndrome. Am J Med Genet A 2004; 131: 82-85.
131. Rainbow LA, Rees SA, Shaikh MG, Shaw NJ, Cole T, Barrett TG, et al. Mutation analysis of POUF-1, PROP-1 and HESX-1 show low frequency of mutations in children with sporadic forms of combined pituitary hormone deficiency and septo-optic dysplasia. Clin Endocrinol (Oxf ) 2005; 62: 163-168.
132. Wales JK, Quarrell OW. Evidence for possible Mendelian inheritance of septo-optic dysplasia. Acta Paediatr 1996; 85: 391-392.
133. Murray PG, Paterson WF, Donaldson MD. Maternal age in patients with septo-optic dysplasia. J Pediatr Endocrinol Metab 2005; 18: 471-476.
134. McNay DE, Turton JP, Kelberman D, Woods KS, Brauner R, Papadimitriou A, et al. HESX1 mutations are an uncommon cause of septooptic dysplasia and hypopituitarism. J Clin Endocrinol Metab 2007; 92: 691-697.
135. Bhangoo AP, Hunter CS, Savage JJ, Anhalt H, Pavlakis S, Walvoord EC, et al. Clinical case seminar: a novel LHX3 mutation presenting as combined pituitary hormonal deficiency. J Clin Endocrinol Metab 2006; 91: 747-753.
136. Machinis K, Amselem S. Functional relationship between LHX4 and POU1F1 in light of the LHX4 mutation identified in patients with pituitary defects. J Clin Endocrinol Metab 2005; 90: 5456-5462.
137. Kamachi Y, Uchikawa M, Collignon J, Lovell-Badge R, Kondoh H. Involvement of Sox1, 2 and 3 in the early and subsequent molecular events of lens induction. Development 1998; 125: 2521-2532.
138. Fantes J, Ragge NK, Lynch SA, McGill NI, Collin JR, Howard-Peebles PN, et al. Mutations in SOX2 cause anophthalmia. Nat Genet 2003; 33: 461-463.
139. Ragge NK, Lorenz B, Schneider A, Bushby K, de Sanctis L, de Sanctis U, et al. SOX2 anophthalmia syndrome. Am J Med Genet A 2005; 135: 1-7.
140. Hagstrom SA, Pauer GJ, Reid J, Simpson E, Crowe S, Maumenee IH, et al. SOX2 mutation causes anophthalmia, hearing loss, and brain anomalies. Am J Med Genet A 2005; 138: 95-98.
141. Zenteno JC, Gascon-Guzman G, Tovilla-Canales JL. Bilateral anophthalmia and brain malformations caused by a 20-bp deletion in the SOX2 gene. Clin Genet 2005; 68: 564-566.
142. Sato N, Kamachi Y, Kondoh H, Shima Y, Morohashi K, Horikawa R, et al. Hypogonadotropic hypogonadism in an adult female with a heterozygous hypomorphic mutation of SOX2. Eur J Endocrinol 2007; 156: 167-171.
143. Kelberman D, de Castro SC, Huang S, Crolla JA, Palmer R, Gregory JW, et al. SOX2 plays a critical role in the pituitary, forebrain and eye during human embryonic development. J Clin Endocrinol Metab 2008; 93: 1865-1873.
144. Roessler E, Du YZ, Mullor JL, Casas E, Allen WP, Gillessen-Kaesbach G, et al. Loss-of-function mutations in the human GLI2 gene are associated with pituitary anomalies and holoprosencephaly-like features. Proc Natl Acad Sci U S A 2003; 100: 13424-13429.
145. Tillmann V, Tang VW, Price DA, Hughes DG, Wright NB, Clayton PE. Magnetic resonance imaging of the hypothalamic-pituitary axis in the diagnosis of growth hormone deficiency. J Pediatr Endocrinol Metab 2000; 13: 1577-1583.
146. Mehta A, Hindmarsh PC, Stanhope RG, Brain CE, Preece MA, Dattani MT. Is the thyrotropin-releasing hormone test necessary in the diagnosis of central hypothyroidism in children. J Clin Endocrinol Metab 2003; 88: 5696-5703.
147. van Tijn DA, de Vijlder JJ, Vulsma T. Role of the thyrotropin-releasing hormone stimulation test in diagnosis of congenital central hypothyroidism in infants. J Clin Endocrinol Metab 2008; 93: 410-419.
148. Mehta A, Hindmarsh PC, Dattani MT. An update on the biochemical diagnosis of congenital ACTH insufficiency. Clin Endocrinol (Oxf) 2005; 62: 307-314.
149. Birkebaek NH, Patel L, Wright NB, Grigg JR, Sinha S, Hall CM, et al. Optic nerve size evaluated by magnetic resonance imaging in children with optic nerve hypoplasia, multiple pituitary hormone deficiency, isolated growth hormone deficiency, and idiopathic short stature. J Pediatr 2004; 145: 536-541.
150. Boulay JL, O'Shea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 2003; 19: 159-163.
151. Liongue C, Ward AC. Evolution of Class I cytokine receptors. BMC Evol Biol 2007; 7: 120.
152. Edens A, Talamantes F. Alternative processing of growth hormone receptor transcripts. Endocr Rev 1998; 19: 559-582.
153. Wei Y, Rhani Z, Goodyer CG. Characterization of growth hormone receptor messenger ribonucleic acid variants in human adipocytes. J Clin Endocrinol Metab 2006; 91: 1901-1908.
154. Rivers CA, Norman MR. The human growth hormone receptor gene: characterisation of the liver-specific promoter. Mol Cell Endocrinol 2000; 160: 51-59.
155. Gates GC, Rhani Z, Zheng H. Expression of the hepatic specific V1 messenger ribonucleic acid of the human growth hormone receptor gene is regulated by hepatic nuclear factor (HNF)-4α2 and HNF-4 α 8. Mol Endocrinol 2008; 22: 485-500.
156. Behncken SN, Waters MJ. Molecular recognition events involved in the activation of the growth hormone receptor by growth hormone. J Mol Recognit 1999; 12: 355-362.
157. Brown RJ, Adams JJ, Pelekanos RA, Wan Y, McKinstry WJ, Palethorpe K, et al. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nat Struct Mol Biol 2005; 12: 814-821.
158. Strous GJ, dos Santos CA, Gent J, Govers R, Sachse M, Schantl J, et al. Ubiquitin system-dependent regulation of growth hormone receptor signal transduction. Curr Top Microbiol Immunol 2004; 286: 81-118.
159. Leung DW, Spencer SA, Cachianes G, Hammonds RG, Collins C, Henzel WJ, et al. Growth hormone receptor and serum binding protein: purification, cloning and expression. Nature 1987; 330: 537-543.
160. Zhang Y, Jiang J, Black RA, Baumann G, Frank SJ. Tumor necrosis factor-alpha converting enzyme (TACE) is a growth hormone binding protein (GHBP) sheddase: the metalloprotease TACE/ADAM-17 is critical for (PMA-induced) GH receptor proteolysis and GHBP generation. Endocrinology 2000; 141: 4342-4348.
161. Carmignac DF, Gabrielsson BG, Robinson IC. Growth hormone binding protein in the rat: effects of gonadal steroids. Endocrinology 1993; 133: 2445-2452.
162. Gevers EF, Wit JM, Robinson IC. Growth, growth hormone (GH)-binding protein, and GH receptors are differentially regulated by peak and trough components of the GH secretory pattern in the rat. Endocrinology 1996; 137: 1013-1018.
163. Baumann G. Growth hormone binding protein: the soluble growth hormone receptor. Minerva Endocrinol 2002; 27: 265-276.
164. Amit T, Youdim MB, Hochberg Z. Clinical review 112: does serum growth hormone (GH) binding protein reflect human GH receptor function? J Clin Endocrinol Metab 2000; 85: 927-932.
165. Savage MO, Attie KM, David A, Metherell LA, Clark AJ, Camacho-Hubner C. Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders. Nat Clin Pract Endocrinol Metab 2006; 2: 395-407.
166. Donaghy AJ, Delhanty PJ, Ho KK, Williams R, Baxter RC. Regulation of the growth hormone receptor/binding protein, insulin-like growth factor ternary complex system in human cirrhosis. J Hepatol 2002; 36: 751-758.
167. Sotiropoulos A, Perrot-Applanat M, Dinerstein H, Pallier A, Postel-Vinay MC, Finidori J, et al. Distinct cytoplasmic regions of the growth hormone receptor are required for activation of JAK2, mitogen-activated protein kinase, and transcription. Endocrinology 1994; 135: 1292-1298.
168. Frank SJ, Gilliland G, Kraft AS, Arnold CS. Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase. Endocrinology 1994; 135: 2228-2239.
169. Soldaini E, John S, Moro S, Bollenbacher J, Schindler U, Leonard WJ. DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol 2000; 20: 389-401.
170. Levy DE, Darnell JE Jr. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002; 3: 651-662.
171. Teglund S, McKay C, Schuetz E, van Deursen JM, Stravopodis D, Wang D, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 1998; 93: 841-850.
172. Liu X, Robinson GW, Wagner KU, Garrett L, Wynshaw-Boris A, Hennighausen L. Stat5a is mandatory for adult mammary gland development and lactogenesis. Genes Dev 1997; 11: 179-186.
173. Choi HK, Waxman DJ. Growth hormone, but not prolactin, maintains, low-level activation of STAT5a and STAT5b in female rat liver. Endocrinology 1999; 140: 5126-5135.
174. Gallego MI, Binart N, Robinson GW, Okagaki R, Coschigano KT, Perry J, et al. Prolactin, growth hormone, and epidermal growth factor activate Stat5 in different compartments of mammary tissue and exert different and overlapping developmental effects. Dev Biol 2001; 229: 163-175.
175. Holloway MG, Cui Y, Laz EV, Hosui A, Hennighausen L, Waxman DJ. Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus. Endocrinology 2007; 148: 1977-1986.
176. Clodfelter KH, Miles GD, Wauthier V, Holloway MG, Zhang X, Hodor P, et al. Role of STAT5a in regulation of sex-specific gene expression in female but not male mouse liver revealed by microarray analysis. Physiol Genomics 2007; 31: 63-74.
177. Udy GB, Towers RP, Snell RG, Wilkins RJ, Park SH, Ram PA, et al. Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A 1997; 94: 7239-7244.
178. Dupuis S, Dargemont C, Fieschi C, Thomassin N, Rosenzweig S, Harris J, et al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 2001; 293: 300-303.
179. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature 2007; 448: 1058-1062.
180. Zhou Y, Xu BC, Maheshwari HG, He L, Reed M, Lozykowski M, et al. A mammalian model for Laron syndrome produced by targeted disruption of the mouse growth hormone receptor/binding protein gene (the Laron mouse). Proc Natl Acad Sci U S A 1997; 94: 13215-13220.
181. Coschigano KT, Clemmons D, Bellush LL, Kopchick JJ. Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. Endocrinology 2000; 141: 2608-2613.
182. Yao Z, Cui Y, Watford WT, Bream JH, Yamaoka K, Hissong BD, et al. Stat5a/b are essential for normal lymphoid development and differentiation. Proc Natl Acad Sci U S A 2006; 103: 1000-1005.
183. Kelly J, Spolski R, Imada K, Bollenbacher J, Lee S, Leonard WJ. A role for Stat5 in CD8+ T cell homeostasis. J Immunol 2003; 170: 210-217.
184. Iavnilovitch E, Groner B, Barash I. Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res 2002; 1: 32-47.
185. Gebert CA, Park SH, Waxman DJ. Down-regulation of liver JAK2-STAT5b signaling by the female plasma pattern of continuous growth hormone stimulation. Mol Endocrinol 1999; 13: 213-227.
186. Gebert CA, Park SH, Waxman DJ. Termination of growth hormone pulse-induced STAT5b signaling. Mol Endocrinol 1999; 13: 38-56.
187. Ahluwalia A, Clodfelter KH, Waxman DJ. Sexual dimorphism of rat liver gene expression: regulatory role of growth hormone revealed by deoxyribonucleic Acid microarray analysis. Mol Endocrinol 2004; 18: 747-760.
188. Waxman DJ, O'Connor C. Growth hormone regulation of sexdependent liver gene expression. Mol Endocrinol 2006; 20: 2613-2629.
189. Davey HW, Park SH, Grattan DR, McLachlan MJ, Waxman DJ. STAT5b-deficient mice are growth hormone pulse-resistant: role of STAT5b in sex-specific liver P450 expression. J Biol Chem 1999; 274: 35331-35336.
190. Clodfelter KH, Holloway MG, Hodor P, Park SH, Ray WJ, Waxman DJ. Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis. Mol Endocrinol 2006; 20: 1333-1351.
191. Tronche F, Opherk C, Moriggl R, Kellendonk C, Reimann A, Schwake L, et al. Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. Genes Dev 2004; 18: 492-497.
192. Eleswarapu S, Gu Z, Jiang H. Growth hormone regulation of IGF-1 gene expression may be mediated by multiple distal STAT5 binding sites. Endocrinology 2008; 149: 2230-2240.
193. Chia DJ, Ono M, Woelfle J, Schlesinger-Massart M, Jiang H, Rotwein P. Characterization of distinct Stat5b binding sites that mediate growth hormone-stimulated IGF-1 gene transcription. J Biol Chem 2006; 281: 3190-3197.
194. Vidal OM, Merino R, Rico-Bautista E, Fernandez-Perez L, Chia DJ, Woelfle J, et al. In vivo transcript profiling and phylogenetic analysis identifies suppressor of cytokine signaling 2 as a direct signal transducer and activator of transcription 5b target in liver. Mol Endocrinol 2007; 21: 293-311.
195. Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, Misawa H, et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 1997; 89: 3148-3154.
196. Wood TJ, Sliva D, Lobie PE, Goullieux F, Mui AL, Groner B, et al. Specificity of transcription enhancement via the STAT responsive element in the serine protease inhibitor 2.1 promoter. Mol Cell Endocrinol 1997; 130: 69-81.
197. Woelfle J, Rotwein P. In vivo regulation of growth hormonestimulated gene transcription by STAT5b. Am J Physiol Endocrinol Metab 2004; 286: E393-E401.
198. Mukhopadhyay SS, Wyszomierski SL, Gronostajski RM, Rosen JM. Differential interactions of specific nuclear factor I isoforms with the glucocorticoid receptor and STAT5 in the cooperative regulation of WAP gene transcription. Mol Cell Biol 2001; 21: 6859-6869.
199. Kim HP, Imbert J, Leonard WJ. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev 2006; 17: 349-366.
200. Greenhalgh CJ, Rico-Bautista E, Lorentzon M, Thaus AL, Morgan PO, Willson TA, et al. SOCS2 negatively regulates growth hormone action in vitro and in vivo. J Clin Invest 2005; 115: 397-406.
201. Gu F, Dube N, Kim JW, Cheng A, Ibarra-Sanchez MJ, Tremblay ML, et al. Protein tyrosine phosphatase 1B attenuates growth hormone-mediated JAK2-STAT signaling. Mol Cell Biol 2003; 23: 3753-3762.
202. Ram PA, Waxman DJ. Interaction of growth hormone-activated STATs with SH2-containing phosphotyrosine phosphatase SHP-1 and nuclear JAK2 tyrosine kinase. J Biol Chem 1997; 272: 17694-17702.
203. Pasquali C, Curchod ML, Walchli S, Espanel X, Guerrier M, Arigoni F, et al. Identification of protein tyrosine phosphatases with specificity for the ligand-activated growth hormone receptor. Mol Endocrinol 2003; 17: 2228-2239.
204. Binder G, Neuer K, Ranke MB, Wittekindt NE. PTPN11 mutations are associated with mild growth hormone resistance in individuals with Noonan syndrome. J Clin Endocrinol Metab 2005; 90: 5377-5381.
205. Lanning NJ, Carter-Su C. Recent advances in growth hormone signaling. Rev Endocr Metab Disord 2006; 7: 225-235.
206. Rowland JE, Lichanska AM, Kerr LM, White M, d'Aniello EM, Maher SL, et al. In vivo analysis of growth hormone receptor signaling domains and their associated transcripts. Mol Cell Biol 2005; 25: 66-77.
207. LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007; 3: 302-310.
208. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47.
209. Luther J, Aitken R, Milne J, Matsuzaki M, Reynolds L, Redmer D, et al. Maternal and fetal growth, body composition, endocrinology, and metabolic status in undernourished adolescent sheep. Biol Reprod 2007; 77: 343-350.
210. Randhawa R, Cohen P. The role of the insulin-like growth factor system in prenatal growth. Mol Genet Metab 2005; 86: 84-90.
211. Davidson S, Hod M, Merlob P, Shtaif B. Leptin, insulin, insulin-like growth factors and their binding proteins in cord serum: insight into fetal growth and discordancy. Clin Endocrinol (Oxf ) 2006; 65: 586-592.
212. Geary MP, Pringle PJ, Rodeck CH, Kingdom JC, Hindmarsh PC. Sexual dimorphism in the growth hormone and insulin-like growth factor axis at birth. J Clin Endocrinol Metab 2003; 88: 3708-3714.
213. Gluckman PD, Gunn AJ, Wray A, Cutfield WS, Chatelain PG, Guilbaud O, et al. Congenital idiopathic growth hormone deficiency associated with prenatal and early postnatal growth failure. The International Board of the Kabi Pharmacia International Growth Study. J Pediatr 1992; 121: 920-923.
214. Rosenbloom AL, Guevara-Aguirre J, Rosenfeld RG, Francke U. Growth hormone receptor deficiency in Ecuador. J Clin Endocrinol Metab 1999; 84: 4436-4443.
215. Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor 1 (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75: 59-72.
216. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73-82.
217. Cediel R, Riquelme R, Contreras J, Diaz A, Varela-Nieto I. Sensorineural hearing loss in insulin-like growth factor I-null mice: a new model of human deafness. Eur J Neurosci 2006; 23: 587-590.
218. Mohan S, Baylink DJ. Impaired skeletal growth in mice with haploinsufficiency of IGF-1: genetic evidence that differences in IGF-1 expression could contribute to peak bone mineral density differences. J Endocrinol 2005; 185: 415-420.
219. Sutter NB, Bustamante CD, Chase K, Gray MM, Zhao K, Zhu L, et al. A single IGF1 allele is a major determinant of small size in dogs. Science 2007; 316: 112-115.
220. Clemmons DR. Role of insulin-like growth factor binding proteins in controlling IGF actions. Mol Cell Endocrinol 1998; 140: 19-24.
221. Twigg SM, Baxter RC. Insulin-like growth factor (IGF)-binding protein 5 forms an alternative ternary complex with IGFs and the acid-labile subunit. J Biol Chem 1998; 273: 6074-6079.
222. Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT. The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 2001; 170: 63-70.
223. Holt RI, Jones JS, Stone NM, Baker AJ, Miell JP. Sequential changes in insulin-like growth factor I (IGF-I) and IGF-binding proteins in children with end-stage liver disease before and after successful orthotopic liver transplantation. J Clin Endocrinol Metab 1996; 81: 160-168.
224. Woods KA, Camacho-Hubner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N Engl J Med 1996; 335: 1363-1367.
225. Beauloye V, Willems B, de C, V, Frank SJ, Edery M, Thissen JP. Impairment of liver GH receptor signaling by fasting. Endocrinology 2002; 143: 792-800.
226. Gleeson HK, Lissett CA, Shalet SM. Insulin-like growth factor-I response to a single bolus of growth hormone is increased in obesity. J Clin Endocrinol Metab 2005; 90: 1061-1067.
227. Bergad PL, Schwarzenberg SJ, Humbert JT, Morrison M, Amarasinghe S, Towle HC, et al. Inhibition of growth hormone action in models of inflammation. Am J Physiol Cell Physiol 2000; 279: C1906-C1917.
228. Tonshoff B, Kiepe D, Ciarmatori S. Growth hormone/insulin-like growth factor system in children with chronic renal failure. Pediatr Nephrol 2005; 20: 279-289.
229. Mahesh S, Kaskel F. Growth hormone axis in chronic kidney disease. Pediatr Nephrol 2008; 23: 41-48.
230. Clemmons DR. Clinical utility of measurements of insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2006; 2: 436-446.
231. Denley A, Carroll JM, Brierley GV, Cosgrove L, Wallace J, Forbes B, et al. Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors. Mol Cell Biol 2007; 27: 3569-3577.
232. Kido Y, Nakae J, Hribal ML, Xuan S, Efstratiadis A, Accili D. Effects of mutations in the insulin-like growth factor signaling system on embryonic pancreas development and beta-cell compensation to insulin resistance. J Biol Chem 2002; 277: 36740-36747.
233. Holzenberger M, Dupont J, Ducos B, Leneuve P, Geloen A, Even PC, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003; 421: 182-187.
234. Gevers EF, van der Eerden BC, Karperien M, Raap AK, Robinson IC, Wit JM. Localization and regulation of the growth hormone receptor and growth hormone-binding protein in the rat growth plate. J Bone Miner Res 2002; 17: 1408-1419.
235. Wang E, Wang J, Chin E, Zhou J, Bondy CA. Cellular patterns of insulin-like growth factor system gene expression in murine chondrogenesis and osteogenesis. Endocrinology 1995; 136: 2741-2751.
236. Lazowski DA, Fraher LJ, Hodsman A, Steer B, Modrowski D, Han VK. Regional variation of insulin-like growth factor-I gene expression in mature rat bone and cartilage. Bone 1994; 15: 563-576.
237. Hunziker EB, Wagner J, Zapf J. Differential effects of insulin-like growth factor I and growth hormone on developmental stages of rat growth plate chondrocytes in vivo. J Clin Invest 1994; 93: 1078-1086.
238. Kaplan SA, Cohen P. The somatomedin hypothesis 2007: 50 years later. J Clin Endocrinol Metab 2007; 92: 4529-4535.
239. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci U S A 1999; 96: 7088-7092.
240. Liu JL, Yakar S, LeRoith D. Mice deficient in liver production of insulin-like growth factor I display sexual dimorphism in growth hormone-stimulated postnatal growth. Endocrinology 2000; 141: 4436-4441.
241. Ueki I, Ooi GT, Tremblay ML, Hurst KR, Bach LA, Boisclair YR. Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system. Proc Natl Acad Sci U S A 2000; 97: 6868-6873.
242. Gevers EF, Milne J, Robinson IC, Loveridge N. Single cell enzyme activity and proliferation in the growth plate: effects of growth hormone. J Bone Miner Res 1996; 11: 1103-1111.
243. Reinecke M, Schmid AC, Heyberger-Meyer B, Hunziker EB, Zapf J. Effect of growth hormone and insulin-like growth factor I (IGF-I) on the expression of IGF-I messenger ribonucleic acid and peptide in rat tibial growth plate and articular chondrocytes in vivo. Endocrinology 2000; 141: 2847-2853.
244. Gevers EF, Robinson IC. GH and Stat5 signaling in vivo: insulin attenuates GH-resistance induced by fasting. Proceedings of the 89th Annual Meeting of The Endocrine Society, Toronto. 2007: 2-388.
245. Palmiter RD, Brinster RL, Hammer RE, Trumbauer ME, Rosenfeld MG, Birnberg NC, et al. Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. Nature 1982; 300: 611-615.
246. Mathews LS, Hammer RE, Behringer RR, D'Ercole AJ, Bell GI, Brinster RL, et al. Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 1988; 123: 2827-2833.
247. Liao L, Dearth RK, Zhou S, Britton OL, Lee AV, Xu J. Liver-specific overexpression of the insulin-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency. Endocrinology 2006; 147: 3877-3888.
248. Sims NA, Clement-Lacroix P, Da Ponte F, Bouali Y, Binart N, Moriggl R, et al. Bone homeostasis in growth hormone receptornull mice is restored by IGF-I but independent of Stat5. J Clin Invest 2000; 106: 1095-1103.
249. Lupu F, Terwilliger JD, Lee K, Segre GV, Efstratiadis A. Roles of growth hormone and insulin-like growth factor 1 in mouse postnatal growth. Dev Biol 2001; 229: 141-162.
250. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, et al. Circulating concentrations of IGF-1 directly regulate bone growth and density. J Clin Invest 2002; 110: 771-781.
251. Kowarski AA, Schneider J, Ben Galim E, Weldon VV, Daughaday WH. Growth failure with normal serum RIA-GH and low somatomedin activity: somatomedin restoration and growth acceleration after exogenous GH. J Clin Endocrinol Metab 1978; 47: 461-464.
252. Takahashi Y, Kaji H, Okimura Y, Goji K, Abe H, Chihara K. Brief report: short stature caused by a mutant growth hormone. N Engl J Med 1996; 334: 432-436.
253. Millar DS, Lewis MD, Horan M, Newsway V, Easter TE, Gregory JW, et al. Novel mutations of the growth hormone 1 (GH1) gene disclosed by modulation of the clinical selection criteria for individuals with short stature. Hum Mutat 2003; 21: 424-440.
254. Petkovic V, Thevis M, Lochmatter D, Besson A, Eble A, Fluck CE, et al. GH mutant (R77C) in a pedigree presenting with the delay of growth and pubertal development: structural analysis of the mutant and evaluation of the biological activity. Eur J Endocrinol 2007; 157 (Suppl 1): S67-S74.
255. Lewis MD, Horan M, Millar DS, Newsway V, Easter TE, Fryklund L, et al. A novel dysfunctional growth hormone variant (Ile179Met) exhibits a decreased ability to activate the extracellular signal-regulated kinase pathway. J Clin Endocrinol Metab 2004; 89: 1068-1075.
256. Besson A, Salemi S, Deladoey J, Vuissoz JM, Eble A, Bidlingmaier M, et al. Short stature caused by a biologically inactive mutant growth hormone (GH-C53S). J Clin Endocrinol Metab 2005; 90: 2493-2499.
257. Laron Z, Pertzelan A, Mannheimer S. Genetic pituitary dwarfism with high serum concentation of growth hormone: a new inborn error of metabolism? Isr J Med Sci 1966; 2: 152-155.
258. Godowski PJ, Leung DW, Meacham LR, Galgani JP, Hellmiss R, Keret R, et al. Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. Proc Natl Acad Sci U S A 1989; 86: 8083-8087.
259. Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. J Clin Endocrinol Metab 2004; 89: 1031-1044.
260. Laron Z, Lilos P, Klinger B. Growth curves for Laron syndrome. Arch Dis Child 1993; 68: 768-770.
261. Woods KA, Dastot F, Preece MA, Clark AJ, Postel-Vinay MC, Chatelain PG, et al. Phenotype: genotype relationships in growth hormone insensitivity syndrome. J Clin Endocrinol Metab 1997; 82: 3529-3535.
262. Walenkamp MJ, van der Kamp HJ, Pereira AM, Kant SG, van Duyvenvoorde HA, Kruithof MF, et al. A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin-like growth factor I receptor. J Clin Endocrinol Metab 2006; 91: 3062-3070.
263. Laron Z, Ginsberg S, Lilos P, Arbiv M, Vaisman N. Body composition in untreated adult patients with Laron syndrome (primary GH insensitivity). Clin Endocrinol (Oxf ) 2006; 65: 114-117.
264. Kranzler JH, Rosenbloom AL, Martinez V, Guevara-Aguirre J. Normal intelligence with severe insulin-like growth factor I deficiency due to growth hormone receptor deficiency: a controlled study in a genetically homogeneous population. J Clin Endocrinol Metab 1998; 83: 1953-1958.
265. Bachrach LK, Marcus R, Ott SM, Rosenbloom AL, Vasconez O, Martinez V, et al. Bone mineral, histomorphometry, and body composition in adults with growth hormone receptor deficiency. J Bone Miner Res 1998; 13: 415-421.
266. Rosenbloom AL, Guevara-Aguirre J, Berg MA, Francke U. Stature in Ecuadorians heterozygous for growth hormone receptor gene E180 splice mutation does not differ from that of homozygous normal relatives. J Clin Endocrinol Metab 1998; 83: 2373-2375.
267. Silbergeld A, Klinger B, Schwartz H, Laron Z. Serum prolactin in patients with Laron-type dwarfism: effect of insulin-like growth factor I. Horm Res 1992; 37: 160-164.
268. Burren CP, Woods KA, Rose SJ, Tauber M, Price DA, Heinrich U, et al. Clinical and endocrine characteristics in atypical and classical growth hormone insensitivity syndrome. Horm Res 2001; 55: 125-130.
269. Sivan B, Lilos P, Laron Z. Effects of insulin-like growth factor-I deficiency and replacement therapy on the hematopoietic system in patients with Laron syndrome (primary growth hormone insensitivity). J Pediatr Endocrinol Metab 2003; 16: 509-520.
270. Christ ER, Cummings MH, Westwood NB, Sawyer BM, Pearson TC, Sonksen PH, et al. The importance of growth hormone in the regulation of erythropoiesis, red cell mass, and plasma volume in adults with growth hormone deficiency. J Clin Endocrinol Metab 1997; 82: 2985-2990.
271. Jeay S, Sonenshein GE, Postel-Vinay MC, Kelly PA, Baixeras E. Growth hormone can act as a cytokine controlling survival and proliferation of immune cells: new insights into signaling pathways. Mol Cell Endocrinol 2002; 188: 1-7.
272. Dorshkind K, Horseman ND. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocr Rev 2000; 21: 292-312.
273. Duquesnoy P, Sobrier ML, Duriez B, Dastot F, Buchanan CR, Savage MO, et al. A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization. EMBO J 1994; 13: 1386-1395.
274. Metherell LA, Akker SA, Munroe PB, Rose SJ, Caulfield M, Savage MO, et al. Pseudoexon activation as a novel mechanism for disease resulting in atypical growth-hormone insensitivity. Am J Hum Genet 2001; 69: 641-646.
275. David A, Camacho-Hubner C, Bhangoo A, Rose SJ, Miraki-Moud F, Akker SA, et al. An intronic growth hormone receptor mutation causing activation of a pseudoexon is associated with a broad spectrum of growth hormone insensitivity phenotypes. J Clin Endocrinol Metab 2007; 92: 655-659.
276. Woods KA, Fraser NC, Postel-Vinay MC, Savage MO, Clark AJ. A homozygous splice site mutation affecting the intracellular domain of the growth hormone (GH) receptor resulting in Laron syndrome with elevated GH-binding protein. J Clin Endocrinol Metab 1996; 81: 1686-1690.
277. Silbergeld A, Dastot F, Klinger B, Kanety H, Eshet R, Amselem S, et al. Intronic mutation in the growth hormone (GH) receptor gene from a girl with Laron syndrome and extremely high serum GH binding protein: extended phenotypic study in a very large pedigree. J Pediatr Endocrinol Metab 1997; 10: 265-274.
278. Ayling RM, Ross R, Towner P, Von Laue S, Finidori J, Moutoussamy S, et al. A dominant-negative mutation of the growth hormone receptor causes familial short stature. Nat Genet 1997; 16: 13-14.
279. Iida K, Takahashi Y, Kaji H, Nose O, Okimura Y, Abe H, et al. Growth hormone (GH) insensitivity syndrome with high serum GH-binding protein concentrations caused by a heterozygous splice site mutation of the GH receptor gene producing a lack of intracellular domain. J Clin Endocrinol Metab 1998; 83: 531-537.
280. Milward A, Metherell L, Maamra M, Barahona MJ, Wilkinson IR, Camacho-Hubner C, et al. Growth hormone (GH) insensitivity syndrome due to a GH receptor truncated after Box1, resulting in isolated failure of STAT 5 signal transduction. J Clin Endocrinol Metab 2004; 89: 1259-1266.
281. Goddard AD, Covello R, Luoh SM, Clackson T, Attie KM, Gesundheit N, et al. Mutations of the growth hormone receptor in children with idiopathic short stature. The Growth Hormone Insensitivity Study Group. N Engl J Med 1995; 333: 1093-1098.
282. Goddard AD, Dowd P, Chernausek S, Geffner M, Gertner J, Hintz R, et al. Partial growth-hormone insensitivity: the role of growthhormone receptor mutations in idiopathic short stature. J Pediatr 1997; 131: S51-S55.
283. Jorge AA, Souza SC, Nishi MY, Billerbeck AE, Liborio DC, Kim CA, et al. SHOX mutations in idiopathic short stature and Leri-Weill dyschondrosteosis: frequency and phenotypic variability. Clin Endocrinol (Oxf ) 2007; 66: 130-135.
284. Chusho H, Tamura N, Ogawa Y, Yasoda A, Suda M, Miyazawa T, et al. Dwarfism and early death in mice lacking C-type natriuretic peptide. Proc Natl Acad Sci U S A 2001; 98: 4016-4021.
285. Bartels CF, Bukulmez H, Padayatti P, Rhee DK, Ravenswaaij-Arts C, Pauli RM, et al. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet 2004; 75: 27-34.
286. Olney RC, Bukulmez H, Bartels CF, Prickett TC, Espiner EA, Potter LR, et al. Heterozygous mutations in natriuretic peptide receptor-B (NPR2) are associated with short stature. J Clin Endocrinol Metab 2006; 91: 1229-1232.
287. Blair JC, Camacho-Hubner C, Miraki MF, Rosberg S, Burren C, Lim S, et al. Standard and low-dose IGF-I generation tests and spontaneous growth hormone secretion in children with idiopathic short stature. Clin Endocrinol (Oxf ) 2004; 60: 163-168.
288. Buckway CK, Selva KA, Pratt KL, Tjoeng E, Guevara-Aguirre J, Rosenfeld RG. Insulin-like growth factor binding protein-3 generation as a measure of GH sensitivity. J Clin Endocrinol Metab 2002; 87: 4754-4765.
289. Dos SC, Essioux L, Teinturier C, Tauber M, Goffin V, Bougneres P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 2004; 36: 720-724.
290. Pantel J, Machinis K, Sobrier ML, Duquesnoy P, Goossens M, Amselem S. Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J Biol Chem 2000; 275: 18664-18669.
291. Sobrier ML, Duquesnoy P, Duriez B, Amselem S, Goossens M. Expression and binding properties of two isoforms of the human growth hormone receptor. FEBS Lett 1993; 319: 16-20.
292. Lettre G, Butler JL, Ardlie KG, Hirschhorn JN. Common genetic variation in eight genes of the GH/IGF1 axis does not contribute to adult height variation. Hum Genet 2007; 122: 129-139.
293. Carrascosa A, Audi L, Fernandez-Cancio M, Esteban C, Andaluz P, Vilaro E, et al. The exon 3-deleted/full-length growth hormone receptor polymorphism did not influence growth response to growth hormone therapy over 2 years in prepubertal short children born at term with adequate weight and length for gestational age. J Clin Endocrinol Metab 2008; 93: 764-770.
294. Binder G, Baur F, Schweizer R, Ranke MB. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J Clin Endocrinol Metab 2006; 91: 659-664.
295. Schreiner F, Stutte S, Bartmann P, Gohlke B, Woelfle J. Association of the growth hormone receptor d3-variant and catch-up growth of preterm infants with birth weight of less than 1500 grams. J Clin Endocrinol Metab 2007; 92: 4489-4493.
296. Raz B, Janner M, Petkovic V, Lochmatter D, Eble A, Dattani MT, et al. Influence of growth hormone receptor d3 and full-length isoforms on growth hormone response and final height in patients with severe growth hormone deficiency. J Clin Endocrinol Metab 2008; 93: 974-980.
297. Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki J, et al. Growth hormone insensitivity associated with a STAT5b mutation. N Engl J Med 2003; 349: 1139-1147.
298. Hwa V, Little B, Adiyaman P, Kofoed EM, Pratt KL, Ocal G, et al. Severe growth hormone insensitivity resulting from total absence of signal transducer and activator of transcription 5b. J Clin Endocrinol Metab 2005; 90: 4260-4266.
299. Vidarsdottir S, Walenkamp MJ, Pereira AM, Karperien M, van Doorn J, van Duyvenvoorde HA, et al. Clinical and biochemical characteristics of a male patient with a novel homozygous STAT5b mutation. J Clin Endocrinol Metab 2006; 91: 3482-3485.
300. Hwa V, Camacho-Hubner C, Little BM, David A, Metherell LA, El Khatib N, et al. Growth hormone insensitivity and severe short stature in siblings: a novel mutation at the exon 13-intron 13 junction of the STAT5b gene. Horm Res 2007; 68: 218-224.
301. Bernasconi A, Marino R, Ribas A, Rossi J, Ciaccio M, Oleastro M, et al. Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. Pediatrics 2006; 118: e1584-e1592.
302. Cohen AC, Nadeau KC, Tu W, Hwa V, Dionis K, Bezrodnik L, et al. Cutting edge: Decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J Immunol 2006; 177: 2770-2774.
303. Snow JW, Abraham N, Ma MC, Herndier BG, Pastuszak AW, Goldsmith MA. Loss of tolerance and autoimmunity affecting multiple organs in STAT5A/5B-deficient mice. J Immunol 2003; 171: 5042-5050.
304. Antov A, Yang L, Vig M, Baltimore D, Van Parijs L. Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol 2003; 171: 3435-3441.
305. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, et al. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet 2007; 39: 75-79.
306. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, et al. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001; 29: 465-468.
307. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, et al. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. Nat Genet 2007; 39: 70-74.
308. Stofega MR, Herrington J, Billestrup N, Carter-Su C. Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B. Mol Endocrinol 2000; 14: 1338-1350.
309. Limal JM, Parfait B, Cabrol S, Bonnet D, Leheup B, Lyonnet S, et al. Noonan syndrome: relationships between genotype, growth, and growth factors. J Clin Endocrinol Metab 2006; 91: 300-306.
310. Ferreira LV, Souza SA, Arnhold IJ, Mendonca BB, Jorge AA. PTPN11 (protein tyrosine phosphatase, nonreceptor type 11) mutations and response to growth hormone therapy in children with Noonan syndrome. J Clin Endocrinol Metab 2005; 90: 5156-5160.
311. Tartaglia M, Gelb BD. Noonan syndrome and related disorders: genetics and pathogenesis. Annu Rev Genomics Hum Genet 2005; 6: 45-68.
312. Walenkamp MJ, Karperien M, Pereira AM, Hilhorst-Hofstee Y, van Doorn J, Chen JW, et al. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J Clin Endocrinol Metab 2005; 90: 2855-2864.
313. Denley A, Wang CC, McNeil KA, Walenkamp MJ, van Duyvenvoorde H, Wit JM, et al. Structural and functional characteristics of the Val44Met insulin-like growth factor I missense mutation: correlation with effects on growth and development. Mol Endocrinol 2005; 19: 711-721.
314. Bonapace G, Concolino D, Formicola S, Strisciuglio P. A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. J Med Genet 2003; 40: 913-917.
315. Coutinho DC, Coletta RR, Costa EM, Pachi PR, Boguszewski MC, Damiani D, et al. Polymorphisms identified in the upstream core polyadenylation signal of IGF1 gene exon 6 do not cause pre-and postnatal growth impairment. J Clin Endocrinol Metab 2007; 92: 4889-4892.
316. Arends N, Johnston L, Hokken-Koelega A, van Duijn C, de Ridder M, Savage M, et al. Polymorphism in the IGF-I gene: clinical relevance for short children born small for gestational age (SGA). J Clin Endocrinol Metab 2002; 87: 2720.
317. Johnston LB, Dahlgren J, Leger J, Gelander L, Savage MO, Czernichow P, et al. Association between insulin-like growth factor I (IGF-I) polymorphisms, circulating IGF-I, and pre-and postnatal growth in two European small for gestational age populations. J Clin Endocrinol Metab 2003; 88: 4805-4810.
318. Domene HM, Bengolea SV, Martinez AS, Ropelato MG, Pennisi P, Scaglia P, et al. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004; 350: 570-577.
319. Domene HM, Scaglia PA, Lteif A, Mahmud FH, Kirmani S, Frystyk J, et al. Phenotypic effects of null and haploinsufficiency of acidlabile subunit in a family with two novel IGFALS gene mutations. J Clin Endocrinol Metab 2007; 92: 4444-4450.
320. Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, Koller D, et al. Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab 2006; 91: 1826-1831.
321. Heath KE, Argente J, Barrios V, Pozo J, Diaz-Gonzalez F, Martos-Moreno GA, et al. Primary acid-labile subunit deficiency due to recessive IGFALS mutations results in postnatal growth deficit associated with low circulating IGF-I and IGFBP-3 concentrations, and hyperinsulinemia. J Clin Endocrinol Metab 2008; 93: 1616-1624.
322. Abuzzahab MJ, Schneider A, Goddard A, Grigorescu F, Lautier C, Keller E, et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N Engl J Med 2003; 349: 2211-2222.
323. Raile K, Klammt J, Schneider A, Keller A, Laue S, Smith R, et al. Clinical and functional characteristics of the human Arg59Ter insulin-like growth factor i receptor (IGF1R) mutation: implications for a gene dosage effect of the human IGF1R. J Clin Endocrinol Metab 2006; 91: 2264-2271.
324. Kawashima Y, Kanzaki S, Yang F, Kinoshita T, Hanaki K, Nagaishi J, et al. Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation. J Clin Endocrinol Metab 2005; 90: 4679-4687.
325. Inagaki K, Tiulpakov A, Rubtsov P, Sverdlova P, Peterkova V, Yakar S, et al. A familial insulin-like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization. J Clin Endocrinol Metab 2007; 92: 1542-1548.
326. Peoples R, Milatovich A, Francke U. Hemizygosity at the insulinlike growth factor I receptor (IGF1R) locus and growth failure in the ring chromosome 15 syndrome. Cytogenet Cell Genet 1995; 70: 228-234.
327. Rujirabanjerd S, Suwannarat W, Sripo T, Dissaneevate P, Permsirivanich W, Limprasert P. De novo subtelomeric deletion of 15q associated with satellite translocation in a child with developmental delay and severe growth retardation. Am J Med Genet A 2007; 143: 271-276.
328. Okubo Y, Siddle K, Firth H, O'Rahilly S, Wilson LC, Willatt L, et al. Cell proliferation activities on skin fibroblasts from a short child with absence of one copy of the type 1 insulin-like growth factor receptor (IGF1R) gene and a tall child with three copies of the IGF1R gene. J Clin Endocrinol Metab 2003; 88: 5981-5988.
329. Gicquel C, Rossignol S, Cabrol S, Houang M, Steunou V, Barbu V, et al. Epimutation of the telomeric imprinting center region on chromosome 11p15 in Silver-Russell syndrome. Nat Genet 2005; 37: 1003-1007.
330. Clemmons DR. Value of insulin-like growth factor system markers in the assessment of growth hormone status. Endocrinol Metab Clin North Am 2007; 36: 109-129.
331. Cianfarani S, Liguori A, Boemi S, Maghnie M, Iughetti L, Wasniewska M, et al. Inaccuracy of insulin-like growth factor (IGF) binding protein (IGFBP)-3 assessment in the diagnosis of growth hormone (GH) deficiency from childhood to young adulthood: association to low GH dependency of IGF-II and presence of circulating IGFBP-3 18-kilodalton fragment. J Clin Endocrinol Metab 2005; 90: 6028-6034.
332. Jorge AA, Souza SC, Arnhold IJ, Mendonca BB. Poor reproducibility of IGF-I and IGF binding protein-3 generation test in children with short stature and normal coding region of the GH receptor gene. J Clin Endocrinol Metab 2002; 87: 469-472.
333. Savage MO, Blum WF, Ranke MB, Postel-Vinay MC, Cotterill AM, Hall K, et al. Clinical features and endocrine status in patients with growth hormone insensitivity (Laron syndrome). J Clin Endocrinol Metab 1993; 77: 1465-1471.
334. Rosenfeld RG, Buckway C, Selva K, Pratt KL, Guevara-Aguirre J. Insulin-like growth factor (IGF) parameters and tools for efficacy: the IGF-I generation test in children. Horm Res 2004; 62 (Suppl 1): 37-43.
335. Guevara-Aguirre J, Rosenbloom AL, Vasconez O, Martinez V, Gargosky SE, Allen L, et al. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage concentrations and to GH-treated GH deficiency. J Clin Endocrinol Metab 1997; 82: 629-633.
336. Backeljauw PF, Underwood LE. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study. J Clin Endocrinol Metab 2001; 86: 1504-1510.
337. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P. Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999; 51: 128-134.
338. Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007; 92: 902-910.
339. Collett-Solberg PF, Misra M. The role of recombinant human insulin-like growth factor-I in treating children with short stature. J Clin Endocrinol Metab 2008; 93: 10-18.
340. Camacho-Hubner C, Rose S, Preece MA, Sleevi M, Storr HL, Miraki-Moud F, et al. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome. J Clin Endocrinol Metab 2006; 91: 1246-1253.
341. Camacho-Hubner C, Underwood LE, Yordam N, Yuksel B, Smith AV, Attie KM, et al. Once daily rhIGF-1/rhIGFBP-3 treatment improves growth in children with severe primary IGF-1 deficiency: results of a multicenter clinical trial. Proceedings of the 88th Annual Meeting of The Endocrine Society, Boston, OR, 40-1: 2006.
342. Clemmons DR. Involvement of insulin-like growth factor-I in the control of glucose homeostasis. Curr Opin Pharmacol 2006; 6: 620-625.
343. Woods KA, Camacho-Hubner C, Bergman RN, Barter D, Clark AJ, Savage MO. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion. J Clin Endocrinol Metab 2000; 85: 1407-1411.
344. Lowman HB, Chen YM, Skelton NJ, Mortensen DL, Tomlinson EE, Sadick MD, et al. Molecular mimics of insulin-like growth factor 1 (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions. Biochemistry 1998; 37: 8870-8878.
345. Coya R, Vela A, Perez dN, Rica I, Castano L, Busturia MA, et al. Panhypopituitarism: genetic versus acquired etiological factors. J Pediatr Endocrinol Metab 2007; 20: 27-36.
346. Sobrier ML, Maghnie M, Vie-Luton MP, Secco A, Di Iorgi N, Lorini R, et al. Novel HESX1 mutations associated with a life-threatening neonatal phenotype, pituitary aplasia, but normally located posterior pituitary and no optic nerve abnormalities. J Clin Endocrinol Metab 2006; 91: 4528-4536.
347. Sobrier ML, Netchine I, Heinrichs C, Thibaud N, Vie-Luton MP, Van Vliet G, et al. Alu-element insertion in the homeodomain of HESX1 and aplasia of the anterior pituitary. Hum Mutat 2005; 25: 503.